Scholarlink

Background <p>The role of low-grade-inflammation in Irritable Bowel Syndrome (IBS) a common disorder of gut-brain interaction is unclear. Association with symptom severity, as well as effects of first line treatments are understudied. In a large cohort of primary care IBS patients (DOMINO trial), a FODMAP-lowering diet application was superior in improving symptoms compared to standard medical therapy (otilonium bromide, OB). We investigated the level of pro-inflammatory markers in this IBS cohort and its changes by the DOMINO application and OB.</p> Methods <p>Inflammatory markers fecal calprotectin (FC), secretory IgA (sIgA), beta-defensin 2 (HBD-2), fecal elastase (Fel-1), and C-reactive protein (CRP) were analyzed at baseline and after 8-week of treatment (diet or medication). In addition, patients filled out questionnaires to score IBS criteria (Rome IV), IBS subtypes, and symptom severity (IBS-SSS). We used Mann-Whitney-U test, Wilcoxon test, Spearman correlation, Kruskal Wallis test and Chi-square analysis to analyze our data.</p> Results <p>In the DOMINO trial, stool and blood samples of 445 patients were collected before and after treatment. At baseline, respectively 9, 19, 15, 20, 2% of the patients showed abnormal levels of CRP, FC, sIgA, HBD-2, and Fel-1 compared to standard thresholds. However, these markers did not correlate with IBS-SSS. In addition, CRP was significantly lower in IBS-C patients compared to other IBS subtypes. After a 8-week treatment with a FODMAP lowering diet application, both HBD-2 and FC were significantly decreased, while only HBD-2 was decreased with OB.</p> Conclusion <p>Inflammatory markers (FC, CRP, sIgA, HBD-2, Fel-1) were not correlated with symptom severity or predictive of treatment response to a FODMAP diet or OB treatment in a large primary care IBS cohort. All markers decreased after 8-week treatment, with significant differences for HBD-2 and FC. The anti-inflammatory effect of both treatments needs to be further investigated. <i>Trial registration</i>: The trial was registered with ClinicalTrials.gov (NCT04270487, registered on 2020-05-04).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A study on the utility of inflammatory biomarkers in primary care irritable bowel syndrome: a sub analysis of the DOMINO randomized trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月23日

查看全文
  • Celine Tack,
  • Karen Van den Houte,
  • Linde Besard,
  • Luc Capiau,
  • Steven Ceulemans,
  • Olivier Gernay,
  • Sophie Maes,
  • Christian Peetermans,
  • Willem Raat,
  • Jeroen Stubbe,
  • Rudy Van Boxstael,
  • Olivia Vandeput,
  • Sophie Van Steenbergen,
  • Bjorn Gehesquière,
  • Jeroen Raes,
  • Jan Tack,
  • Florencia Carbone

摘要

Background

The role of low-grade-inflammation in Irritable Bowel Syndrome (IBS) a common disorder of gut-brain interaction is unclear. Association with symptom severity, as well as effects of first line treatments are understudied. In a large cohort of primary care IBS patients (DOMINO trial), a FODMAP-lowering diet application was superior in improving symptoms compared to standard medical therapy (otilonium bromide, OB). We investigated the level of pro-inflammatory markers in this IBS cohort and its changes by the DOMINO application and OB.

Methods

Inflammatory markers fecal calprotectin (FC), secretory IgA (sIgA), beta-defensin 2 (HBD-2), fecal elastase (Fel-1), and C-reactive protein (CRP) were analyzed at baseline and after 8-week of treatment (diet or medication). In addition, patients filled out questionnaires to score IBS criteria (Rome IV), IBS subtypes, and symptom severity (IBS-SSS). We used Mann-Whitney-U test, Wilcoxon test, Spearman correlation, Kruskal Wallis test and Chi-square analysis to analyze our data.

Results

In the DOMINO trial, stool and blood samples of 445 patients were collected before and after treatment. At baseline, respectively 9, 19, 15, 20, 2% of the patients showed abnormal levels of CRP, FC, sIgA, HBD-2, and Fel-1 compared to standard thresholds. However, these markers did not correlate with IBS-SSS. In addition, CRP was significantly lower in IBS-C patients compared to other IBS subtypes. After a 8-week treatment with a FODMAP lowering diet application, both HBD-2 and FC were significantly decreased, while only HBD-2 was decreased with OB.

Conclusion

Inflammatory markers (FC, CRP, sIgA, HBD-2, Fel-1) were not correlated with symptom severity or predictive of treatment response to a FODMAP diet or OB treatment in a large primary care IBS cohort. All markers decreased after 8-week treatment, with significant differences for HBD-2 and FC. The anti-inflammatory effect of both treatments needs to be further investigated. Trial registration: The trial was registered with ClinicalTrials.gov (NCT04270487, registered on 2020-05-04).